Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate

Oncologist

Volumn 10, Issue 6, 2005, Pages 457-458

  Garipidou, Vassilia ^a   Vakalopoulou, Sofia ^a   Tziomalos, Konstantinos ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Chronic myeloid leukemia; Erk 1 2 mitogen activated protein kinases; Imatinib mesylate; Multiple myeloma

Indexed keywords

DEXAMETHASONE; IMATINIB; MELPHALAN; PREDNISONE;

AGED; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG MECHANISM; HUMAN; HUMAN CELL; LETTER; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MULTIPLE MYELOMA; PIPERAZINES; PYRIMIDINES;

EID: 22244458317     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-6-457     Document Type: Letter

References (4)

1. Nitta M, Tsuboi K, Yamashita S et al. Multiple myeloma preceding the development of chronic myelogenous leukemia. Int J Hematol 1999;69:170-173.
2. Tanaka M, Kimura R, Matsutani A et al. Coexistence of chronic myelogenous leukemia and multiple myeloma. Case report and review of the literature. Acta Haematol 1998;99:221-223.
3. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-1050.
4. Pandiella A, Carvajal-Vergara X, Tabera S et al. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 2003;123:858-868.